Lead Product(s) : FP-025
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The randomised, double-blind, placebo-controlled, multi-centre study will assess the efficacy and safety of the highly selective FP-025. The subjects will be randomised in 1:1:1 ratio to receive FP-025 100mg or 300mg or placebo twice daily for 28 days.
Product Name : FP-025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2021
Lead Product(s) : FP-025
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FP-025
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $47.0 million
Deal Type : Financing
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
Details : The proceeds of the Public Offering will be used for supporting Foresee’s existing drug research and development programs – such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of...
Product Name : FP-025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 24, 2020
Lead Product(s) : FP-025
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $47.0 million
Deal Type : Financing
Reset All
